ArticleViruses2026
FluEvoFormer: A Structure-Guided Generative Foundation Model for Prospective Influenza Antigenic Evolution and Vaccine Strain Selection.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seasonal influenza vaccine strain selection remains challenging because circulating viruses may drift after vaccine recommendations are made. This study presents FluEvoFormer, a structure-guided generative foundation model for prospective influenza antigenic evolution forecasting and vaccine strain ranking. The framework jointly encodes hemagglutinin and neuraminidase sequences and incorporates residue-contact graphs. Separate prediction heads estimate future viral dominance and the vaccine-virus antigenic match. Controlled future-like variant stress testing, uncertainty adjustments, and clade balancing are then used to rank vaccine candidates. A rolling retrospective evaluation was performed for target seasons involving the influenza A(H1N1)pdm09 virus and influenza A(H3N2) virus. The evaluation used cutoff-restricted sequence records, hemagglutination inhibition data, vaccine-composition records, protein-structure resources, and vaccine-effectiveness indicators. The historical training corpus for the influenza A(H1N1) virus also contained pre-2009 seasonal records. FluEvoFormer achieved the lowest held-out antigenicity prediction error, with mean absolute error (MAE) values of 0.389 for the combined historical influenza A(H1N1) virus corpus and 0.456 for the influenza A(H3N2) virus corpus. It also improved the future dominance prediction, with Kullback-Leibler (KL) divergence values of 0.255 and 0.289, respectively. The model selected candidates with higher empirical normalized coverage scores in seven out of 10 influenza A(H1N1)pdm09 virus seasons and nine out of 10 influenza A(H3N2) virus seasons. The predicted coverage score showed a strong positive correlation with external vaccine-effectiveness estimates. These findings support FluEvoFormer as a computational decision-support framework for prioritizing influenza vaccine candidates before downstream laboratory and public health evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.